Enterprise Value
-275.3M
Cash
1.039B
Avg Qtr Burn
-79.43M
Short % of Float
5.54%
Insider Ownership
2.68%
Institutional Own.
94.29%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Vepdegestrant (ARV-471) (oral ER-targeting PROTAC® protein degrader) Details Breast cancer, Cancer, Solid tumor/s | Phase 3 Data readout | |
Vepdegestrant (ARV-471) (oral ER-targeting PROTAC® protein degrader) + palbociclib Details Breast cancer, Cancer, Solid tumor/s | Phase 3 Data readout | |
ARV-766 +/- abiraterone Details Solid tumor/s, Cancer, Prostate cancer, Castration-resistant prostate cancer | Phase 1/2 Data readout | |
Bavdegalutamide (ARV-110) (PROTAC protein degrader) +/- abiraterone Details Prostate cancer, Cancer, Castration-resistant prostate cancer, Solid tumor/s | Phase 1/2 Update |